Hepatitis C News and Research

Latest Hepatitis C News and Research

Series of new clinical trials confirm range of viable treatment options for HCV patients

Series of new clinical trials confirm range of viable treatment options for HCV patients

2 Apr 2011
Encouraging early data from HCV vaccine phase I trial presented at International Liver Congress

Encouraging early data from HCV vaccine phase I trial presented at International Liver Congress

2 Apr 2011
Results of Boehringer Ingelheim's BI 201335 study presented at Annual Meeting of EASL

Results of Boehringer Ingelheim's BI 201335 study presented at Annual Meeting of EASL

1 Apr 2011
Biota receives US$231 million BARDA contract to advance laninamivir development

Biota receives US$231 million BARDA contract to advance laninamivir development

1 Apr 2011
Donation after cardiac death may broaden the scope of organ donor selection

Donation after cardiac death may broaden the scope of organ donor selection

1 Apr 2011
New findings from two modeling studies can help reduce HCV-related deaths in Europe

New findings from two modeling studies can help reduce HCV-related deaths in Europe

1 Apr 2011
Lymphocyte-hepatocyte interactions: Hepatitis C virus changes the rules

Lymphocyte-hepatocyte interactions: Hepatitis C virus changes the rules

1 Apr 2011
Tibotec presents TMC435 phase 2b study interim results against HCV at EASL meeting

Tibotec presents TMC435 phase 2b study interim results against HCV at EASL meeting

1 Apr 2011
New data confirms antiviral activity of fluvastatin in patients with HCV

New data confirms antiviral activity of fluvastatin in patients with HCV

1 Apr 2011
Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

1 Apr 2011
Vertex announces final results from Phase 3 REALIZE study against HCV

Vertex announces final results from Phase 3 REALIZE study against HCV

1 Apr 2011
Conatus CTS-1027 Phase 2 trial results against HCV presented at EASL meeting

Conatus CTS-1027 Phase 2 trial results against HCV presented at EASL meeting

1 Apr 2011
Treatment for HBV infection with entecavir followed by lamivudine results in virologic rebound

Treatment for HBV infection with entecavir followed by lamivudine results in virologic rebound

1 Apr 2011
Sequential treatment with Entecavir and Lamivudine results in rebound of hepatitis B virus

Sequential treatment with Entecavir and Lamivudine results in rebound of hepatitis B virus

31 Mar 2011
Sinovac reports fourth quarter net sales of $9.1 million

Sinovac reports fourth quarter net sales of $9.1 million

31 Mar 2011
Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C

Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C

31 Mar 2011
Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV

Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV

31 Mar 2011
NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

31 Mar 2011
Master regulators of cholesterol and fat play key role in liver fibrosis development

Master regulators of cholesterol and fat play key role in liver fibrosis development

31 Mar 2011
Boceprevir drug can help cure hard-to-treat hepatitis C

Boceprevir drug can help cure hard-to-treat hepatitis C

31 Mar 2011

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback